查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1649496

全球抗高血压药物市场：预测（2025-2030）

Global Anti-Hypertensive Drug Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球抗高血压药物市场预计将以 2.88% 的复合年增长率成长，到 2025 年达到 410.82 亿美元，到 2030 年达到 472.41 亿美元。

由于不健康的生活方式导致的高血压盛行率不断上升，预计未来五年抗高血压药物市场将显着增长。此外，老龄人口的成长是这些药物需求增加的一个主要因素，因为老年人比年轻人更容易患高血压。高血压是全世界过早死亡的主要原因。有许多因素会导致高血压，包括过度吸烟、慢性压力、慢性肾臟病、大量饮酒和肥胖。吸烟者和饮酒者数量的增加，尤其是千禧世代的增加，预计将为市场提供巨大的成长机会，因为这些生活方式的选择预计会导致高血压发病率上升。此外，成年人肥胖率的不断上升可能会推动未来几年对抗高血压药物的需求。快速的都市化和全球化也导致公共卫生状况的恶化。生活方式的改变、压力水平的增加以及不健康的饮食和睡眠习惯都会导致血压升高，预计未来五年将对抗高血压药物市场的成长产生积极影响。

抗高血压药物市场的关键驱动因素

  • 高血压盛行率上升：高血压盛行率上升是抗高血压药物市场发展的主要驱动力。吸烟和过量摄取现像日益普遍，尤其是在新兴经济体中，极大地推动了对这些药物的需求。根据世界卫生组织 (WHO) 的数据，高血压影响全球约 11.3 亿人，其中大多数居住在中低收入国家。世界卫生组织到2025年将高血压盛行率降低25%的目标预计也将增加对这些药物的需求。
  • 公共卫生挑战：这些药物在应对重大公共卫生挑战中所扮演的角色凸显了其必要性。高血压会显着增加心血管疾病的风险，因此保持较低的血压有助于降低中风、心臟病发作和心臟衰竭的风险。

地理视角

  • 亚太地区：抗高血压药物市场分为北美、南美、欧洲、中东和非洲以及亚太等地区。由于吸烟率高和不健康的生活习惯导致印度和中国等新兴国家的高血压发病率上升，预计亚太地区将显着增长。
  • 北美：该地区预计将占据抗高血压药物市场的大部分份额，因为肥胖和缺乏运动等生活习惯是导致高血压的因素。随着年龄增长，罹患高血压的风险也会增加。北美先进的医疗保健体系提供了透过创新的医疗技术进行有效治疗的机会。大型製药公司开发或销售抗高血压药物的存在进一步推动了该地区市场的发展。人们对高血压风险的认识不断提高，以及更新、更有效的药物的出现也可能对市场扩张产生积极的促进作用。

总之，由于高血压盛行率的上升和人口老化，抗高血压药物市场预计将经历显着增长。从区域来看，由于影响健康结果的不同社会经济因素，亚太地区和北美预计将在这一扩张中发挥关键作用。

为什么要购买这份报告？

  • 深刻分析：获得深入的市场洞察，涵盖主要和新兴地区，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透率。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中开闢新的业务流和收益。
  • 适合广泛的用户：对于新兴企业、研究机构、顾问公司、中小企业和大型企业来说，它都是实用且具有成本效益的。

它有什么用途？

产业与市场分析、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

研究范围

  • 2022 年至 2030 年的实际资料和预测
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争定位、策略与市场占有率分析
  • 各地区（包括细分市场和国家）的收益成长和预测分析
  • 公司概况（策略、产品、财务、主要发展等）

目录

第 1 章 简介

  • 市场概况
  • 市场定义
  • 研究范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 研究过程

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
  • 产业价值链分析

第 5 章 全球抗高血压药物市场（依药物类别划分）

  • 介绍
  • 利尿剂
  • β受体阻断剂
  • ACI 抑制剂
  • 钙离子通道阻断剂
  • α阻断剂与β受体阻断剂合併使用
  • 其他的

第六章全球抗高血压药物市场（按类型）

  • 介绍
  • 原发性高血压
  • 次发性高血压

第七章 全球抗高血压药物市场依销售管道

  • 介绍
  • 处方笺
  • 场外交易（OTC）

第 8 章 全球抗高血压药物市场区域分布

  • 介绍
  • 北美洲
    • 按药品类别
    • 按类型
    • 按销售管道
    • 按国家
  • 南美洲
    • 按药品类别
    • 按类型
    • 按销售管道
    • 按国家
  • 欧洲
    • 按药品类别
    • 按类型
    • 按销售管道
    • 按国家
  • 中东和非洲
    • 按药品类别
    • 按类型
    • 按销售管道
    • 按国家
  • 亚太地区
    • 按药品类别
    • 按类型
    • 按销售管道
    • 按国家

第九章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争仪錶板

第十章 公司简介

  • Boehringer Ingelheim International GmbH
  • DAIICHI SANKYO COMPANY, LIMITED
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • Merck and Co. Inc.
  • Lupin Pharmaceuticals, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb and Company
简介目录
Product Code: KSI061613517

The global anti-hypertensive drug market is estimated to grow at a CAGR of 2.88% to reach a market size of US$47.241 billion in 2030 from US$41.082 billion in 2025.

The global anti-hypertensive drug market is expected to experience significant growth over the next five years, driven by the increasing prevalence of hypertension linked to unhealthy lifestyles. Additionally, the growing geriatric population is a major factor contributing to the rising demand for these medications, as older adults are more prone to high blood pressure compared to younger individuals. Hypertension is a leading cause of premature deaths worldwide.Several factors contribute to the rise in high blood pressure, including excessive smoking, chronic stress, chronic kidney disease, high alcohol consumption, and obesity. The increasing number of smokers and alcohol consumers, particularly among millennials, is projected to create substantial growth opportunities for the market as hypertension rates are expected to rise due to these lifestyle choices. Furthermore, the growing obesity rates among adults will likely drive demand for anti-hypertensive drugs in the coming years.Rapid urbanization and globalization are also deteriorating public health conditions. Changing lifestyles, increased stress levels, and unhealthy eating and sleeping habits contribute to higher blood pressure, which is anticipated to positively influence the growth of the anti-hypertensive drug market over the next five years.

Key Drivers of the Global Anti-Hypertensive Drug Market

  • Rising Prevalence of Hypertension: The increasing incidence of hypertension is a primary driver for the anti-hypertensive drug market. The growing number of smokers and individuals with excessive alcohol consumption-especially in developing economies-significantly boosts demand for these medications. According to the World Health Organization (WHO), approximately 1.13 billion people worldwide suffer from hypertension, with a majority residing in low- and middle-income countries. WHO's goal to reduce hypertension prevalence by 25% by 2025 is also expected to enhance demand for these drugs.
  • Public Health Challenge: The necessity of these medications is underscored by their role in addressing a major public health challenge. Hypertension significantly increases the risk of cardiovascular diseases; thus, controlling elevated blood pressure levels can help reduce the risks of strokes, heart attacks, and heart failures.

Geographical Outlook

  • Asia Pacific: The global anti-hypertensive drug market is segmented into regions including North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The Asia Pacific region is projected to witness notable growth due to rising hypertension rates in developing countries like India and China, driven by high smoking rates and unhealthy lifestyles. Additionally, an increasing geriatric population in many APAC nations supports market growth.
  • North America: This region is expected to maintain a significant share of the anti-hypertensive drug market due to lifestyle factors such as obesity and physical inactivity contributing to hypertension. The aging population makes individuals more susceptible to developing high blood pressure. North America's advanced healthcare system provides opportunities for effective treatment through innovative medical technologies. The presence of leading pharmaceutical companies developing or marketing anti-hypertensive drugs further fuels market growth in this region. Increased awareness about hypertension risks and the availability of new potent medications will also contribute positively to market expansion.

In summary, the global anti-hypertensive drug market is set for substantial growth driven by rising hypertension prevalence and an aging population. Geographically, both Asia Pacific and North America are expected to play crucial roles in this expansion due to distinct socio-economic factors influencing health outcomes.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Market Segmentation:

The global anti-hypertensive drug market is segmented and analyzed as below:

By Drug Class

  • Diuretics
  • Beta-Blockers
  • ACI Inhibitors
  • Calcium Channel Blockers
  • Combined Alpha and Beta-Blockers
  • Others

By Type

  • Primary Hypertension
  • Secondary Hypertension

By Sales Channel

  • Prescription
  • Over-the-counter (OTC)

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY DRUG CLASS

  • 5.1. Introduction
  • 5.2. Diuretics
  • 5.3. Beta-Blockers
  • 5.4. ACI Inhibitors
  • 5.5. Calcium Channel Blockers
  • 5.6. Combined Alpha and Beta-Blockers
  • 5.7. Others

6. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY TYPE

  • 6.1. Introduction
  • 6.2. Primary Hypertension
  • 6.3. Secondary Hypertension

7. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY SALES CHANNEL

  • 7.1. Introduction
  • 7.2. Prescription
  • 7.3. Over-the-counter (OTC)

8. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Drug Class
    • 8.2.2. By Type
    • 8.2.3. By Sales Channel
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Drug Class
    • 8.3.2. By Type
    • 8.3.3. By Sales Channel
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Drug Class
    • 8.4.2. By Type
    • 8.4.3. By Sales Channel
    • 8.4.4. By Country
      • 8.4.4.1. Germany
      • 8.4.4.2. France
      • 8.4.4.3. United Kingdom
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Drug Class
    • 8.5.2. By Type
    • 8.5.3. By Sales Channel
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. Israel
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Drug Class
    • 8.6.2. By Type
    • 8.6.3. By Sales Channel
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. South Korea
      • 8.6.4.4. India
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Taiwan
      • 8.6.4.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Boehringer Ingelheim International GmbH
  • 10.2. DAIICHI SANKYO COMPANY, LIMITED
  • 10.3. Novartis AG
  • 10.4. Pfizer Inc.
  • 10.5. Johnson & Johnson
  • 10.6. Merck and Co. Inc.
  • 10.7. Lupin Pharmaceuticals, Inc.
  • 10.8. Sanofi S.A.
  • 10.9. Sun Pharmaceutical Industries Ltd.
  • 10.10. Bristol-Myers Squibb and Company